SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high ahead of its Q3 results is driving attention, alongside bullish options activity and expectations for continued BRIUMVI growth. Traders are also speculating about a potential buyout or short squeeze, though others caution that the run may already reflect strong earnings expectations and that no deal is confirmed.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa has traders focused on whether the FDA will accept it for review and grant priority review. Bulls see regulatory progress and the drugs potential as support, while skeptics worry about approval risk, a go-it-alone launch, and possible future dilution without a partnership or buyout.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owls Q3 earnings beat expectations, and traders are focusing on stronger fee-related earnings, dividend coverage, and future fees from uninvested capital. The reaction is bullish, though concerns about private-credit redemptions persist and options activity suggests traders remain divided.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARM is selling off with semiconductor peers, with traders linking the decline to Intels weak outlook and broader chip-sector pressure while questioning ARMs rich valuation. Dip buyers counter that AI-driven CPU demand supports the long-term story, with earnings approaching.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

Discussion centers on the TRUMP meme coins steep decline, with many traders calling it a cash grab and lamenting losses while others expect a speculative rebound. Election-related speculation adds to the polarized bull-versus-bear debate, but no confirmed new catalyst dominates.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm is drawing attention ahead of its fiscal Q1 earnings report, with traders weighing expectations for continued GMV and revenue growth against concerns about high rates, consumer credit quality, and valuation. The community is split between bulls expecting another strong update and bears warning that macro pressure could weigh on the BNPL lender.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Bitwise XRP ETF is drawing attention amid volatile XRP trading, with traders pointing to ETF inflows and possible regulatory clarity as supportive themes. Optimism about institutional demand contrasts with frustration over losses and confusion between the ETF shares and XRP itself.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are drawing attention after rising on Q3 results and an upbeat Q4 profit outlook, with premium subscriber growth and stronger gross margin outweighing a revenue and EPS miss for many traders. The reaction is split: bulls focus on the guidance and user momentum, while skeptics question the rally amid rising expenses and valuation concerns.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention as natural-gas weakness and repeated lows weigh on the leveraged ETF, with traders citing mild winter forecasts, storage builds and losses from futures rolling and daily leverage. Some are buying for a possible cold-weather or polar-vortex rebound, while bears argue that oversupply and fund decay remain headwinds.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter results, which topped analyst expectations on growth from Dupixent and Eylea HD, have driven a sharp rally and a new 52-week high. Traders are broadly upbeat about the companys growth across multiple drugs, while some caution that declining legacy Eylea sales remain a risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WisdomTree Trust - WisdomTree Emerging Markets ex-State-Owned Enterprises Fund

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

XSOE News